Communications Biology (Jul 2024)

A MYCN-driven de-differentiation profile identifies a subgroup of aggressive retinoblastoma

  • Tatsiana Ryl,
  • Elena Afanasyeva,
  • Till Hartmann,
  • Melanie Schwermer,
  • Markus Schneider,
  • Christopher Schröder,
  • Maren Wagemanns,
  • Arthur Bister,
  • Deniz Kanber,
  • Laura Steenpass,
  • Kathrin Schramm,
  • Barbara Jones,
  • David T. W. Jones,
  • Eva Biewald,
  • Kathy Astrahantseff,
  • Helmut Hanenberg,
  • Sven Rahmann,
  • Dietmar R. Lohmann,
  • Alexander Schramm,
  • Petra Ketteler

DOI
https://doi.org/10.1038/s42003-024-06596-6
Journal volume & issue
Vol. 7, no. 1
pp. 1 – 16

Abstract

Read online

Abstract Retinoblastoma are childhood eye tumors arising from retinal precursor cells. Two distinct retinoblastoma subtypes with different clinical behavior have been described based on gene expression and methylation profiling. Using consensus clustering of DNA methylation analysis from 61 retinoblastomas, we identify a MYCN-driven cluster of subtype 2 retinoblastomas characterized by DNA hypomethylation and high expression of genes involved in protein synthesis. Subtype 2 retinoblastomas outside the MYCN-driven cluster are characterized by high expression of genes from mesodermal development, including NKX2-5. Knockdown of MYCN expression in retinoblastoma cell models causes growth arrest and reactivates a subtype 1-specific photoreceptor signature. These molecular changes suggest that removing the driving force of MYCN oncogenic activity rescues molecular circuitry driving subtype 1 biology. The MYCN-RB gene signature generated from the cell models better identifies MYCN-driven retinoblastoma than MYCN amplification and can identify cases that may benefit from MYCN-targeted therapy. MYCN drives tumor progression in a molecularly defined retinoblastoma subgroup, and inhibiting MYCN activity could restore a more differentiated and less aggressive tumor biology.